These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31718855)

  • 1. Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review.
    Beck A; Retèl VP; Bhairosing PA; van den Brekel M; van Harten WH
    Health Policy; 2019 Dec; 123(12):1185-1198. PubMed ID: 31718855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient access to voice prostheses and heat and moisture exchangers: Factors influencing physician's prescription and reimbursement in eight European countries.
    Beck ACC; Retèl VP; van den Brekel MWM; van Harten WH
    Oral Oncol; 2019 Apr; 91():56-64. PubMed ID: 30926063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].
    Stordeur S; Vinck I; Neyt M; Van Brabandt H; Hulstaert F
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):105-10. PubMed ID: 23477881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments.
    Ciani O; Wilcher B; van Giessen A; Taylor RS
    Health Econ; 2017 Feb; 26 Suppl 1():13-29. PubMed ID: 28139087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which barriers prevent the efficient use of resources in medical device sectors?
    Simoens S
    Appl Health Econ Health Policy; 2009; 7(4):209-17. PubMed ID: 19905034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes device reimbursement in the EU-5.
    Schäfer E; Schnell G; Bobáková T
    J Diabetes Sci Technol; 2013 Jul; 7(4):1084-92. PubMed ID: 23911192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations.
    Tarricone R; Banks H; Ciani O; Brouwer W; Drummond MF; Leidl R; Martelli N; Sampietro-Colom L; Taylor RS
    Expert Rev Med Devices; 2023 Apr; 20(4):259-271. PubMed ID: 36987818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for an institution for evaluation of diabetes technology devices to improve their quality in the European Union.
    Heinemann L; Freckmann G; Koschinsky T
    J Diabetes Sci Technol; 2013 Mar; 7(2):542-7. PubMed ID: 23567012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
    Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
    Health Policy; 2019 Jul; 123(7):630-634. PubMed ID: 31130319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing adoption and affordability of medical devices in Europe.
    Schreyögg J; Bäumler M; Busse R
    Health Policy; 2009 Oct; 92(2-3):218-24. PubMed ID: 19410326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A full-fledged overhaul is needed for a risk and value-based regulation of medical devices in Europe.
    Campillo-Artero C
    Health Policy; 2013 Nov; 113(1-2):38-44. PubMed ID: 23602548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neither protective nor harmonized: the crossborder regulation of medical devices in the EU.
    Jarman H; Rozenblum S; Huang TJ
    Health Econ Policy Law; 2021 Jan; 16(1):51-63. PubMed ID: 32631465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Physician Payments Sunshine Act--Two Years of the Open Payments Program.
    Agrawal S; Brown D
    N Engl J Med; 2016 Mar; 374(10):906-9. PubMed ID: 26962725
    [No Abstract]   [Full Text] [Related]  

  • 17. Obtaining reimbursement in France and Italy for new diabetes products.
    Schaefer E; Schnell G; Sonsalla J
    J Diabetes Sci Technol; 2015 Jan; 9(1):156-61. PubMed ID: 25550411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
    Lee SS; Salole E
    Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?
    Tarricone R; Torbica A; Ferré F; Drummond M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):707-18. PubMed ID: 25196848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In search of a travel guide-results from a survey of E‑health startup companies].
    Hagen J; Lauer W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Mar; 61(3):291-297. PubMed ID: 29404630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.